Navigation Links
Routine blood test predicts prognosis in aggressive skin cancer
Date:10/31/2012

BOSTON, MA (October 31, 2012)A routine blood test may help predict survival in patients with an aggressive form of skin cancer known as Merkel cell carcinoma, according to new findings by Fox Chase Cancer Center researchers. The results will be presented on Wednesday, October 31 at the American Society for Radiation Oncology's 54th Annual Meeting.

"With such a fast-growing cancer, we get one question a lot: 'how long do I have?'," says Matthew Johnson, MD, a resident physician in the Department of Radiation Oncology at Fox Chase and lead author on the study. "That's usually hard to answer. These findings enable us to give a more educated response."

Specifically, Johnson and his colleagues found that patients with Merkel cell carcinoma who had low numbers of lymphocytesa type of white blood cell that participates in immune functiondidn't live as long after treatment as those with higher lymphocyte counts.

The difference was remarkable. Among people whose absolute lymphocyte count (ALC) was below the cutoff (1500 cells per cubic millimeter of blood, or 1.5 k/mm3), half survived 25 months or less after surgery, chemotherapy, or radiation. Among those with ALCs in the normal range, half lived close to 100 months or more following treatment. Disease-free survival was also much longer in patients with higher ALCs.

"Since ALC has been tied to prognosis in other types of cancer, we were expecting to see some difference between patients with high and low counts," says Johnson. "But it was definitely a bigger difference than what we were anticipating."

Merkel cell carcinoma is a rare and aggressive type of skin cancer, usually striking older people and those with weakened immune systems.

During the study, Johnson and his team reviewed medical records of 64 patients treated for Merkel cell carcinoma between 1992 and 2010 at Fox Chase. All patients had had their blood analyzed the month before surgery, chemotherapy, or radiation.

Approximately two-thirds of patients had a normal ALC. Along with having longer overall survival, these patients were much more likely to be disease-free 60 months later (67%) than those with a low ALC (24%).

ALC may be associated with survival because it's a marker of overall immune health, says Johnson, and healthier immune systems may keep a cancer in check so it doesn't continue to grow.

Doctors routinely check a patient's ALC as part of a standard blood count, says Johnson. They just typically don't know how to interpret those particular results. Since checking a patient's ALC is already routine, it would be "reasonable, based on our conclusions," for a patient to ask his or her doctor for the results of that test, he notes.

However, if a patient's ALC is particularly low, there's little the doctor would do differently to treat Merkel cell carcinoma, since such an aggressive cancer is always treated aggressively. But many patients believe it's helpful to know their prognosis, he says.

"ALC provides patients with some information about how long they may have left. There are a lot of patients who just want to know."


'/>"/>
Contact: Diana Quattrone
Diana.Quattrone@fccc.edu
215-728-7784
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. Routine mammograms may result in significant overdiagnosis of invasive breast cancer
2. Routine Kidney Disease Screening Not Worthwhile, Experts Say
3. Doctors Urge Routine Skin Screenings
4. U.S. Advisers Say No to Routine PSA Tests for Prostate Cancer
5. Routine care for Crohns disease in children should include measurement of bone age
6. Not Enough Data to Advise Routine Hearing Screens for Older People: Experts
7. Routine Screening Wont Cut Rates of Domestic Violence, Study Suggests
8. Routine electrocardiograms predict health risks for patients with atrial fibrillation
9. Infection Might Raise Blood Clot Risk for Older Adults: Study
10. Normalizing tumor blood vessels improves delivery of only the smallest nanomedicines
11. Common Blood Pressure Drug Safe for Heart Failure: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... AlignLife clinics nationwide are giving back to their communities by collecting toys ... gifts wrapped tightly under a Christmas Tree. AlignLife hopes to spread the joy ... In exchange for generous donations, customers will receive a gift in return. Anyone ...
(Date:12/7/2016)... ... December 07, 2016 , ... Facial plastic surgeon, Dr. John D. Rachel ... a portion of proceeds to two local organizations: North Chicago Animal Control and Friends ... is a team of authorized and trained volunteers who support rescued animals held ...
(Date:12/7/2016)... ... 07, 2016 , ... "ProBrand Flip allows FCPX editors to create unique logo ... CEO of Pixel Film Studios. , ProBrand Flip includes 30 flip book reveal animations. ... select from a variety of flip book animations. In Addition, users can modify each ...
(Date:12/7/2016)... ... ... “Tomorrow Trump Goes To Washington”: a brief but engaging illustration depicting the first ... Trump Goes To Washington” is the creation of published author, Nancy Engestrom, a hardworking ... attributes her patriotic nature to her WWII veteran father. She says, “I love ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... was honored to present at the International Probiotic Association’s Washington DC workshop on ... government regulators to engage in dialog regarding probiotic dietary supplement regulations. , ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... 2016 The pen needles market is projected ... 1.65 billion in 2016, growing at a CAGR of ... Over the years, the pen needles market has ... the growing demand for safety injections in the healthcare ... safety pen needles with an aim to reduce pain, ...
(Date:12/6/2016)...  BTL Aesthetics today announced the release of ... ME device was effectively redesigned for more efficient, ... tissue. The result: Significantly better outcomes in abdominal ... ME versus BTL Vanquish. "We are ... patients with the most highly-advanced devices on the ...
(Date:12/6/2016)... 6, 2016  Viking Therapeutics, Inc. ("Viking") (NASDAQ: ... focused on the development of novel therapies for ... U.S. Food and Drug Administration (FDA) has granted ... of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a novel, ... selectively regulates the expression of genes believed to ...
Breaking Medicine Technology: